@annexonbio.com
Unlocking the next generation of complement therapies We are focused on stopping C1q, the initiating molecule of the classical complement pathway, at the start to treat devastating autoimmune, neurodegenerative, and ophthalmic diseases of the body, brain and eye.
📢
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
Icon
PNG
About
Description
Annexon Biosciences is a cutting-edge biotech brand that is dedicated to developing innovative therapies for complement-driven diseases. Complement-driven diseases refer to autoimmune, neurodegenerative, and ophthalmic diseases of the body, brain, and eye. At Annexon Biosciences, their mission is to target C1q, the initiating molecule of the classical complement pathway, to block all damaging components of the immune system's classical complement pathway.
By doing so, they aim to halt the progression of these devastating diseases at their very start. With a robust pipeline of early complement inhibitors, Annexon Biosciences is poised to unlock the potential of the next generation of complement therapies. Their team of passionate researchers and scientists are dedicated to delivering transformative therapies that will improve the lives of those suffering from complement-driven diseases.
For the latest news and updates, Annexon Biosciences invites you to visit their website or contact them directly. Join them in their mission to revolutionize the treatment landscape and make a difference in the lives of patients
Company Type
Public Company
Company Size
51-200
Year Founded
2011
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere 👋
All services online